- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Bortezomib pinanediol ester
【Catalogue Number】AP0102
【CAS #】205393-22-2
【Molecular formula】 C29H39BN4O4
【Introduction】Bortezomib pinanediol ester, the English name is Bortezomib-Pinanediol, the American Chemical Abstracts Registry number is cas 205393-22-2.
Bortezomib pinanediol ester
CAS 205393-22-2
Other name Butezomipine diol
Catalog number AP0102
CAS # 205393-22-2
Molecular formula C29H39BN4O4
Molecular weight 518.46
Structural formula
Product introduction
CAS 205393-22-2 Bortezomib alkyl diol ester, English name is Bortezomib-Pinanediol, American Chemical Abstracts Registration Number is cas 205393-22-2.
Bortezomib oxanediol ester (cas 205393-22-2) is an intermediate of bortezomib. Bortezomib is a reversible inhibitor of 26S proteasome chymotrypsin-like activity in mammalian cells. Proteolysis can affect the cascade of multilevel signals in the cell, and this damage to the normal intracellular environment can lead to cell death. Inhibition of the 26S proteasome prevents hydrolysis of specific proteins. In vitro tests have proven that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor model in vivo tests have demonstrated that bortezomib can delay tumor growth, including multiple myeloma. Bortezomib can be used in the treatment of patients with multiple myeloma.
VIWIT 沪ICP备12014533号-1
